Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $109.1 million.

  • Apellis Pharmaceuticals' Net Cash Flow rose 19781.37% to $109.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 24650.06%. This contributed to the annual value of $61.0 million for FY2024, which is 13034.79% up from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Net Cash Flow of $109.1 million as of Q3 2025, which was up 19781.37% from $11.0 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' Net Cash Flow's 5-year high stood at $356.4 million during Q4 2021, with a 5-year trough of -$298.4 million in Q1 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median Net Cash Flow value was -$6.8 million (recorded in 2022), while the average stood at -$4.4 million.
  • The largest annual percentage gain for Apellis Pharmaceuticals' Net Cash Flow in the last 5 years was 323338.72% (2023), contrasted with its biggest fall of 71705.26% (2023).
  • Over the past 5 years, Apellis Pharmaceuticals' Net Cash Flow (Quarter) stood at $356.4 million in 2021, then plummeted by 109.14% to -$32.6 million in 2022, then plummeted by 212.59% to -$101.8 million in 2023, then soared by 115.07% to $15.3 million in 2024, then soared by 611.3% to $109.1 million in 2025.
  • Its Net Cash Flow stands at $109.1 million for Q3 2025, versus $11.0 million for Q2 2025 and -$53.1 million for Q1 2025.